PFE · PFIZER INC · Top AI ETF

Back to holdings

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19.

Close · 3M

+6.70%

Held by 3 AI ETFs

LQAI1.840%

as of Sep 2

AIVL0.551%

as of Sep 3

BUZZ0.250%

as of Sep 2

Signal performance

Each tracked ETF's moves on this stock, grouped by fund. Returns are measured from the signal date to the latest close — hypothetical, no commissions or slippage.

Buy signals20

Win rate100% (20/20)

Avg buy return+6.98%

LQAInow 1.840% of fund11 signals

LQAI · Accumulation · 5d

weight 1.980% → 2.030% (+0.050 pp)·stock up 13.8% in the 30 days before

Aug 31·entry $28.46·now $28.81Fresh

+1.23%

since Aug 31

LQAI · Weight decrease · 2d

weight 2.040% → 1.990% (-0.050 pp)·stock up 11.4% in the 30 days before

Aug 27·entry $28.02·now $28.81

+2.82%

since Aug 27

LQAI · Accumulation · 5d

weight 1.860% → 2.020% (+0.160 pp)·stock up 12.1% in the 30 days before

Aug 26·entry $28.30·now $28.81Fresh

+1.80%

since Aug 26

LQAI · Accumulation · 5d

weight 1.860% → 2.040% (+0.180 pp)·stock up 15.8% in the 30 days before

Aug 25·entry $28.57·now $28.81Fresh

+0.84%

since Aug 25

LQAI · Weight increase · 2d

weight 1.980% → 2.010% (+0.030 pp)·stock up 14.0% in the 30 days before

Aug 24·entry $27.97·now $28.81Drifting

+3.00%

since Aug 24

LQAI · Weight increase · 2d

weight 1.860% → 2.000% (+0.140 pp)·stock up 13.2% in the 30 days before

Aug 19·entry $28.24·now $28.81Drifting

+2.02%

since Aug 19

LQAI · Weight decrease · 2d

weight 1.950% → 1.880% (-0.070 pp)·stock up 8.5% in the 30 days before

Aug 12·entry $26.31·now $28.81

+9.50%

since Aug 12

LQAI · Weight increase · 3d

weight 1.620% → 1.950% (+0.330 pp)·stock up 11.9% in the 30 days before

Aug 10·entry $27.05·now $28.81Drifting

+6.51%

since Aug 10

LQAI · Weight increase · 2d

weight 1.620% → 1.920% (+0.300 pp)·stock up 10.4% in the 30 days before

Aug 7·entry $26.76·now $28.81Drifting

+7.66%

since Aug 7

LQAI · Weight increase · 2d

stock up 3.2% in the 30 days before

Jul 29·entry $25.15·now $28.81Chased

+14.55%

since Jul 29

LQAI · Weight decrease · 3d

stock down 1.0% in the 30 days before

Jul 22·entry $24.82·now $28.81

+16.08%

since Jul 22

AIVLnow 0.551% of fund13 signals

AIVL · Weight decrease · 3d

weight 0.647% → 0.631% (-0.015 pp)·stock up 12.2% in the 30 days before

Aug 28·entry $27.96·now $28.81

+3.04%

since Aug 28

AIVL · Weight decrease · 2d

weight 0.647% → 0.634% (-0.013 pp)·stock up 11.4% in the 30 days before

Aug 27·entry $28.02·now $28.81

+2.82%

since Aug 27

AIVL · Accumulation · 5d

weight 0.597% → 0.647% (+0.050 pp)·stock up 15.8% in the 30 days before

Aug 25·entry $28.57·now $28.81Fresh

+0.84%

since Aug 25

AIVL · Accumulation · 5d

weight 0.593% → 0.636% (+0.043 pp)·stock up 12.2% in the 30 days before

Aug 21·entry $28.07·now $28.81Drifting

+2.64%

since Aug 21

AIVL · Weight increase · 3d

weight 0.597% → 0.636% (+0.039 pp)·stock up 13.2% in the 30 days before

Aug 19·entry $28.24·now $28.81Drifting

+2.02%

since Aug 19

AIVL · Weight increase · 2d

weight 0.597% → 0.615% (+0.017 pp)·stock up 10.1% in the 30 days before

Aug 18·entry $27.25·now $28.81Drifting

+5.72%

since Aug 18

AIVL · Weight decrease · 2d

weight 0.610% → 0.593% (-0.017 pp)·stock up 8.5% in the 30 days before

Aug 12·entry $26.31·now $28.81

+9.50%

since Aug 12

AIVL · Accumulation · 5d

weight 0.191% → 0.602% (+0.410 pp)·stock up 8.7% in the 30 days before

Aug 11·entry $26.62·now $28.81Drifting

+8.23%

since Aug 11

AIVL · Accumulation · 6d

weight 0.189% → 0.610% (+0.421 pp)·stock up 11.9% in the 30 days before

Aug 10·entry $27.05·now $28.81Drifting

+6.51%

since Aug 10

AIVL · Accumulation · 5d

weight 0.194% → 0.602% (+0.409 pp)·stock up 10.4% in the 30 days before

Aug 7·entry $26.76·now $28.81Drifting

+7.66%

since Aug 7

AIVL · Accumulation · 5d

stock up 8.9% in the 30 days before

Aug 6·entry $26.20·now $28.81Drifting

+9.96%

since Aug 6

AIVL · Accumulation · 5d

stock up 4.7% in the 30 days before

Jul 31·entry $25.01·now $28.81Chased

+15.19%

since Jul 31

AIVL · Weight increase · 2d

stock up 3.2% in the 30 days before

Jul 29·entry $25.15·now $28.81Chased

+14.55%

since Jul 29

BUZZnow 0.250% of fund4 signals

BUZZ · Weight decrease · 2d

weight 0.390% → 0.370% (-0.020 pp)·stock up 8.5% in the 30 days before

Aug 12·entry $26.31·now $28.81

+9.50%

since Aug 12

BUZZ · Weight increase · 3d

stock up 3.2% in the 30 days before

Jul 29·entry $25.15·now $28.81Chased

+14.55%

since Jul 29

BUZZ · Weight increase · 2d

stock up 4.0% in the 30 days before

Jul 28·entry $25.25·now $28.81Chased

+14.10%

since Jul 28

BUZZ · Weight decrease · 2d

stock down 1.1% in the 30 days before

Jul 21·entry $24.94·now $28.81

+15.52%

since Jul 21

AIEQno longer held1 signal

AIEQ · Exit · 1d

stock up 4.7% in the 30 days before

Aug 2·entry $25.03·now $28.81

+15.10%

since Aug 2

Sell signals show what the stock did after the AI exited. A negative number means the AI's exit was well-timed.

Buffett-style framework

Too hard to callas of Aug 23

The AI ETFs show mixed activity with Pfizer, including both accumulation and decrease in weight by various funds. However, a Buffett-style analysis concludes that Pfizer is 'Too Hard' to evaluate due to the inherent unpredictability of its business model over a ten-year horizon, suggesting a fundamental divergence in evaluation approach from the active AI-managed strategies.

Circle of CompetenceThe pharmaceutical industry's reliance on patent cycles, R&D success, and regulatory approvals makes projecting Pfizer's unit economics and cash flows over a ten-year horizon genuinely unpredictable.
Economic MoatEvaluation of an economic moat is not conducted as the company falls outside the circle of competence for predictable cash flow projections.
ManagementAssessment of management quality is not performed as the business is deemed too complex for reliable long-term forecasting.
Financial HealthDetailed financial health analysis is omitted because the inherent unpredictability of the business's earning power makes standard metrics less meaningful for long-term valuation.
Margin of SafetyA margin of safety cannot be determined without a reliable intrinsic value estimate, which is impossible due to the unpredictability of future cash flows.

Pfizer operates within the pharmaceutical industry, which is characterized by significant uncertainties related to patent expirations, R&D outcomes, and regulatory approvals. These factors make it genuinely unpredictable to project the company's unit economics and cash flows over a ten-year period, placing it outside the necessary circle of competence for this investing framework. Consequently, a comprehensive evaluation beyond the initial stage is declined, resulting in a 'Too Hard' verdict.

Educational interpretation generated by AI applying frameworks Warren Buffett documented in his shareholder letters and other public writings. Not a statement by Mr. Buffett or Berkshire Hathaway, and not investment advice.